Drug intelligence / Profile preview

isocarboxazid

Development stage
Approved
Lead developer
Roche
Modality
Small Molecules
Administration
Oral
01

Overview

Isocarboxazid is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class used primarily as an antidepressant for the treatment of depression, especially in patients who have not responded to other antidepressants[1][2][3][7]. It works by irreversibly inhibiting both monoamine oxidase-A (MAO-A) and monoamine oxidase-B (MAO-B), enzymes responsible for breaking down neurotransmitters such as serotonin, norepinephrine, dopamine, and epinephrine in the brain[5][6][8]. By blocking these enzymes, isocarboxazid increases the levels of these neurotransmitters at synaptic sites throughout the central nervous system. This elevation in biogenic amines underlies its antidepressant effects. Isocarboxazid has also been investigated for use in anxiety disorders, panic disorders, phobias, schizophrenia, Parkinson's disease, and dementia-related disorders[3][7]. Due to significant food and drug interactions—particularly with substances containing tyramine—and risk of hypertensive crisis or serotonin syndrome when combined with certain drugs or foods high in dietary amines, its use has become less common compared to newer classes of antidepressants such as SSRIs[7].

Brand names
Marplan
Other names
isocarboxazidaisocarboxazideisocarboxazidum
02

Targets

MAOB (Monoamine oxidase B)MAOA (Monoamine oxidase A)

Beyond the preview

Go deeper on isocarboxazid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on isocarboxazid.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call